Daniela Semedo, PhD,  —

Volatile compounds released by the bacteria Pseudomonas aeruginosa fuel the growth of a fungal pathogen found in lung infections in cystic fibrosis (CF) patients, according to a study recently published in the American Society for Microbiology (ASM) journal mBio. The study, “Volatile Compounds Emitted by Pseudomonas…

Nivalis Therapeutics, Inc., recently announced an expanded clinical development plan for N91115, the company’s first-in-class stabilizer of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which is defective in patients with cystic fibrosis (CF). An independent Data Monitoring Committee (DMC) completed a review of interim safety results from the ongoing…

An innovative research center providing tailored physical activity and exercise regimens for young people with cystic fibrosis (CF) has been launched with support for the Cystic Fibrosis Trust. The center will benefit from the skills of an international team of specialists, led by Professor Craig Williams and Dr. Alan Barker from the University of Exeter, U.K.,…

Savara Pharmaceuticals recently announced that it has closed a $20 million Series C financing round, which will be used to advance a pivotal Phase 3 clinical trial of AeroVanc (vancomycin hydrochloride inhalation powder), the first dry powder inhaled antibiotic being developed for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic fibrosis…

As part of the annual “March on the Hill” event in Washington, D.C., sponsored by the Cystic Fibrosis Foundation, Texas volunteers joined other advocates from across the U.S. to present Rep. Lloyd Doggett with the Legislative Champion Award for his efforts on behalf of the cystic fibrosis (CF) community. Congressman Doggett,…

XENiOS, a privately held medical device company specializing in minimally invasive lung-and-heart assistance, recently announced it has invested $2.6 million in  XOR-Labs Toronto, a spin-off of Toronto General Hospital at University Health Network (UHN) that is working to make more donor lungs available to patients needing transplants because of injuries…

Vertex Pharmaceuticals Incorporated recently announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) to its supplemental New Drug Application (sNDA) for Kalydeco (ivacaftor) as a treatment for cystic fibrosis patients ages 2 and older with one of 23 residual function mutations in the cystic fibrosis transmembrane conductance…

Arch Biopartners, Inc, announced that it recently submitted an orphan drug designation application to the European Medicines Authority (EMA) for its product AB569, a potential treatment of pulmonary infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis (CF). The EMA is now reviewing the application, and the Committee for Orphan Medicinal Products…

Parents of a child born with a severe genetic condition such as cystic fibrosis (CF) are greatly affected by their child’s illness and likely to favor early prenatal testing of future pregnancies, researchers at Plymouth University, U.K., report. Their study, “Impact of fetal or child loss on parents’ perceptions of non-invasive prenatal diagnosis for…

The Mayo University Hospital in Ireland has a new €1.4 million day care center for young cystic fibrosis (CF) patients, a much-needed addition in a country with the highest incidence and highest carrier rate of CF in the world. The center, which opened on Jan. 15, 2016, was developed through collaboration between…